AstraZeneca will invest in VaxEquity, a spin-off of Imperial College London, expanding its portfolio into self-amplifying RNA (saRNA) therapeutics.

The saRNA platform uses similar technology to messenger RNA but has self-amplifying abilities that enable proteins to be expressed for longer, delivering higher protein levels per dose.

The Anglo-Swedish drugmaker will provide VaxEquity with an undisclosed amount of research and development funding and up to $195 million in future milestones-based payments, in addition to royalties.

Under the deal, AstraZeneca has an option to collaborate with the company on up to 26 drug targets.